SCHEMBL2928668

SCHEMBL2928668

CSc1cnc2c(ccn2S(=O)(=O)c2ccccc2)c1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.58
L3MBTL1 Q9Y468 2/20 0.48
HTR6 P50406 10/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
HPGD P15428 2/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
TSHR P16473 1/20 0.47
HTT P42858 1/20 0.47
PKM P14618 1/20 0.45
POLB P06746 1/20 0.44
RAPGEF4 Q8WZA2 1/20 0.43
FGFR4 P22455 1/20 0.42
MET P08581 1/20 0.42
HTR1A P08908 1/20 0.40
DRD2 P14416 1/20 0.40
BRD4 O60885 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1963205 0.86 CYP2C19 (0.54) CYP2C19L3MBTL1HTR6MEN1KMT2A
SCHEMBL1958833 0.83 CYP2C19 (0.61) CYP2C19L3MBTL1HTR6MEN1KMT2A
SCHEMBL299699 0.81 CYP2C19 (0.61) CYP2C19L3MBTL1HTR6MEN1KMT2A
SCHEMBL1962403 0.81 CYP2C19 (0.61) CYP2C19L3MBTL1HTR6MEN1KMT2A
SCHEMBL18346376 0.81 CYP2C19 (0.61) CYP2C19L3MBTL1HTR6MEN1KMT2A
SCHEMBL10142546 0.81 CYP2C19 (0.61) CYP2C19L3MBTL1HTR6MEN1KMT2A
SCHEMBL1960656 0.81 CYP2C19 (0.61) CYP2C19L3MBTL1HTR6MEN1KMT2A
SCHEMBL1359397 0.81 CYP2C19 (0.61) CYP2C19L3MBTL1HTR6MEN1KMT2A
SCHEMBL27873188 0.80 CYP2C19 (0.57) CYP2C19L3MBTL1HTR6MEN1KMT2A
SCHEMBL1683418 0.80 HTR6 (0.62) CYP2C19L3MBTL1HTR6MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1086950-B1 HETEROCYCLIC INDOLE DERIVATIVES AND MONO- OR DIAZAINDOLE DERIVATIVES CHUGAI PHARMACEUTICAL CO LTD (JP) 2010-09-29 EP disclosed
US-7612070-B2 Heterocyclic compounds as antiinflammatory agents and cyclooxygenase inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-11-03 US disclosed
US-20050137202-A1 Indole derivative having heterocycle and mono- or diazaindole derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2005-06-23 US disclosed
US-6875770-B2 Indole derivative having heterocycle and mono- or diazaindole derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2005-04-05 US disclosed
US-20040067964-A1 Indole derivative having heterocycle and mono- or diazaindole derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2004-04-08 US disclosed
US-6673797-B1 CYCLOOXYGENASE-2 INHIBITORS; TREATING INFLAMMATORY DISEASE INDUCED BY CYCLOOXYGENASE-2 CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2004-01-06 US disclosed
EP-1086950-A1 HETEROCYCLIC INDOLE DERIVATIVES AND MONO- OR DIAZAINDOLE DERIVATIVES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2001-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137202-A1 Indole derivative having heterocycle and mono- or diazaindole derivative PTGS2, IDO2, IDO1 CYP2C19 60/4885L3MBTL1 4654/4885HTR6 171/4885
US-20040067964-A1 Indole derivative having heterocycle and mono- or diazaindole derivative IDO1, PTGS1, IDO2 CYP2C19 55/4885L3MBTL1 4686/4885HTR6 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.